Navigation Links
Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug

ents treated with other camptothecin-based drugs. The study is ongoing and Insert expects to enter Phase II studies later this year or early next year.

"It is gratifying to see that the Cyclosert system is working as designed in patients," said Dr. Mark Davis, inventor of the technology and Insert's Scientific Founder. "We are looking forward to completing this trial and moving into multiple Phase II studies."

About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.

About Insert Therapeutics

Insert Therapeutics, Inc. (www.insertt.com), a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), is using its proprietary, nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create an entirely new class of biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. Insert's affiliate company, Calando Pharmaceuticals, is using a related system for the systemic delivery of siRNA. The companies are pursuing this goal through internal research and development, and also through collaborations and partnership
'"/>




Page: 1 2 3

Related medicine technology :

1. Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting
2. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
3. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
4. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
5. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
6. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
7. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
8. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
9. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
10. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
11. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
Post Your Comments:
(Date:12/19/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... results on Thursday, January 22, 2015, after the New York ... will be issued after 1:00 p.m. US Pacific Time and ... and future outlook. The earnings call is scheduled ... live webcast of the call can be accessed on ResMed,s ...
(Date:12/19/2014)... , Dec. 18, 2014 Since last ... the site now known as the leading online black ... seen explosive growth in its offering of drugs and ... Alliance show the takedowns did succeed in lowering the ... last review of the markets in August. But some ...
(Date:12/19/2014)... LYON, France , Dec. 19, 2014 ... ) and Adocia (Euronext Paris: FR0011184241 – ADOC) today ... ultra-rapid insulin, known as BioChaperone Lispro, for treatment in ... Lispro relies on Adocia,s proprietary BioChaperone® technology and is ... Adocia will develop BioChaperone Lispro with the goal of ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... Inc. (Nasdaq: STXS ) today announced that executive ... Conference on Tuesday, September 28, 2010 at 8:30 a.m. ET ... an overview of the Company,s business strategy and recent corporate ... invitation only. A live audio and slides webcast of Stereotaxis, ...
... BEDFORD, Mass., Sept. 23 Instrumentation Laboratory (IL), today announced ... on Wednesday, October 13, 2010 at the Grand Hyatt Nusa ... am to 12:00 pm, local time.  The forum will focus ... hemostasis.  All healthcare professionals, practicing in the Asia Pacific region ...
Cached Medicine Technology:Stereotaxis to Present at the JMP Securities Healthcare Conference 2Stereotaxis to Present at the JMP Securities Healthcare Conference 3Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 2Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 3Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 4
(Date:12/19/2014)... Montrose, Colorado (PRWEB) December 20, 2014 It’s ... many, travel is something that is put to the wayside ... those who still have that travel “itch” and that burning ... Inn Montrose accommodates families on their journey to Telluride with ... trip, get visitors to and from the resort, and ensure ...
(Date:12/19/2014)... December 19, 2014 Energy Textiles ... are now available. Celliant, the world’s leading responsive ... and pillowcases. , There are a number of ... circulation, increased oxygenation and balanced body temperature; which ... and pain relief; enhanced athletic performance; and overall ...
(Date:12/19/2014)... 2014 SuperCloset raises the bar once ... continues to offer indoor growers the most efficient and ... new SuperClone Rooms with the award winning SuperRooms ... hydroponic grow room setup. , The SuperClone Room features ... SuperCloner 50 . The SuperClone Room ...
(Date:12/19/2014)... 20, 2014 An evening dress is perfect ... lady’s closet. Discount-Dress.com, a distinguished dresses retailer, has unveiled its ... dresses in this great shopping platform. Customers can ... staff's hard work, Discount-Dress.com has been accepted and praised by ... and easier shopping stage for clients. In order to expand ...
(Date:12/19/2014)... (HealthDay News) -- New research warns parents that buying an older ... Nearly half of teen drivers killed in the United States ... 11 years old and often lacked important safety features that are ... teen drivers killed in crashes were in cars at least six ... old, 31 percent were in cars 11 to 15 years old, ...
Breaking Medicine News(10 mins):Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Older Cars a Bad Choice for Younger Drivers 2
... who are diagnosed with bone cancer could benefit from better ... University of Nottingham. The Bone Cancer Research Trust launches ... project at the University which is testing a theory that ... Researchers at the School of Clinical Sciences, Division of ...
... Reporter , MONDAY, Oct. 11 (HealthDay News) -- The ... involving human embryonic stem cells has been injected with ... patient, being cared for at the Shepherd Center in ... The center specializes in treating these types of injuries. ...
... last six months of life has become progressively more expensive ... the United States and older adults in Canada, with a ... life in both countries, according to two reports posted online ... issue of Archives of Internal Medicine , one of ...
... intravitreous (into the eye) injection of a chemotherapy drug ... against the eye diseasedo not appear to be associated ... when compared with existing therapies, according to a report ... , one of the JAMA/Archives journals. "More than ...
... Oct. 11 (HealthDay News) -- Women with epilepsy may be at ... The study included 375 women who planned to have a ... or for up to 10 years. During the study period, 62 ... among women with epilepsy was more than twice the 15 percent ...
... of a computer or television screen are more likely to ... The PEACH project, a study of over a 1,000 ... spent in front of a screen as well as their ... children,s sedentary time and moderate physical activity. The results ...
Cached Medicine News:Health News:Hope for a new treatment for bone cancer 2Health News:First Patient Treated in U.S.-Approved Embryonic Stem Cell Trial 2Health News:First Patient Treated in U.S.-Approved Embryonic Stem Cell Trial 3Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 2Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 3Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 4Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 5Health News:Certain new therapies for age-related eye disease do not appear to increase heart risks 2Health News:Study Sees Link Between Epilepsy, Infertility 2Health News:Screen time linked to psychological problems in children 2
The ultimate combination of comfort, convenience and affordability, recommended for daily wear, also approved for extended wear (1-7 days)....
SofLens Multi-Focal with unique Natra-Sight Optics designed to provide broad transition for near, intermediate and far vision, SofLens Multi-Focal lenses offer crisp, clear vision at all distances....
... With the Hertel, the unit ... and held firmly against the ... with the center of the ... the two temporal orbital walls, ...
Fastest, easiest and least expensive method for measuring exophthalmos. By sighting at right angles, this device eliminates parallax and allows the clinician to measure the amount of protrusion or bu...
Medicine Products: